In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported that Baker Bros. Advisors has picked up 5,032,313 of common stock as of 2017-04-11.
The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 5,032,313 representing a 15.2% stake in the company.
For those not familiar with the company, Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-601 and BPX-701. The Company’s CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
A glance at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM)’s key stats reveals a current market capitalization of 457.66 Million based on 32.16 Million shares outstanding and a price at last close of $12.86 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-24, Baker picked up 151,177 at a purchase price of $12.00. This brings their total holding to 4,527,089 as of the date of the filing.
On the sell side, the most recent transaction saw Slawin unload 30,000 shares at a sale price of $12.54. This brings their total holding to 294,982.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
